Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02381236 · ClinicalTrials.gov registry record · Phase 2
G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer
A Phase 2 study of Prostatic Neoplasms, sponsored by GenSpera.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
- 1
- Study location
NCT02381236 is a Phase 2 study of Prostatic Neoplasms that has completed, run by GenSpera. The registered enrollment target is 1 participants, below the 514-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02381236, a Phase 2 study of Prostatic Neoplasms, has completed, sponsored by GenSpera.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
A single-arm, open-label Phase II clinical trial to evaluate the effect of G-202 on the perfusion and volume of the prostate using non-invasive multiparametric prostate magnetic resonance imaging (mpMRI).
Conditions Studied
Interventions
- DRUG G-202
Study Locations (1)
Texas
- University of Texas Health Sciences Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-02 |
| Est. Completion | 2017-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02381236
The ClinicalTrials.gov registry entry for NCT02381236 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 514-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (100% lower). The listed sponsor is GenSpera, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostatic Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which G-202 is the first listed.
NCT02381236 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02381236 about?
NCT02381236 is a clinical study titled "G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer". A single-arm, open-label Phase II clinical trial to evaluate the effect of G-202 on the perfusion and volume of the prostate using non-invasive multiparametric prostate magnetic resonance imaging (mpMRI).
What is the current status of trial NCT02381236?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2016-02. Estimated completion is 2017-02.
What conditions does trial NCT02381236 study?
This clinical trial studies the following conditions: Prostatic Neoplasms.
What interventions are being tested in trial NCT02381236?
The interventions under investigation include: G-202 (DRUG).
Who is sponsoring clinical trial NCT02381236?
This trial is sponsored by GenSpera, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02381236 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
RECRUITING · Phase 2
-
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
RECRUITING · Phase 2
-
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
RECRUITING · Phase 2
-
18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
ACTIVE NOT RECRUITING · Phase 2
-
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.